The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.63, representing a -3.14% change from its previous ...
Recursion Pharmaceuticals Inc. stocks have been trading down by -4.08 percent after cautious reaction to its latest AI ...
ARK Invest sold $17.1M in Twist Bioscience shares and purchased Recursion Pharmaceuticals, Intellia Therapeutics, and ...
Tempus AI slides 7.63% today to $77.22 as selling pressure emerges despite bullish momentum and FDA clearance news.
ARK Invest sold Twist Bioscience shares and bought Recursion Pharmaceuticals, Intellia Therapeutics, and Veracyte stock on ...
Pune, India, October 6th, 2026, FinanceWireThis is a paid advertisement.Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ...
Cathie Wood's ARK Invest executed a $22 million healthcare portfolio rotation on Monday, selling approximately $18 million of ...
- Recursion Pharmaceuticals RXRX+16.63% (RXRX) surges 16.38% on heavy volume, trading near $4.83 intraday high. - Extended 2029 Tempus AI TEM +8.11% partnership replaces $84M potential fees with $42M ...
Recursion’s August business update highlighted that Genentech opted its first neuroscience target into an early discovery ...
Recursion Pharmaceuticals Inc. stocks have been trading up by 15.41 percent amid heightened optimism over its AI-driven drug ...
Recursion Pharmaceuticals Inc. surged as breakthrough AI-driven drug discovery progress fueled bullish sentiment, and stocks ...
Tempus AI Inc. stocks have been trading up by 6.55 percent after bullish coverage on its AI-driven healthcare data platform.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results